Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: An hypothesis

Atherosclerosis

Volumn 141, Issue 1, 1998, Pages 17-30

  Watts, G F ^a   Playford, D A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Diabetes mellitus; Dyslipoproteinaemia; Endothelial dysfunction; Nitric oxide; Oxidative stress

Indexed keywords

ARGININE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; NITRIC OXIDE; VERY LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; ATHEROSCLEROSIS; DYSLIPOPROTEINEMIA; ENDOTHELIUM INJURY; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN METABOLISM; MICROANGIOPATHY; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 0032487560     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00170-1     Document Type: Article

References (201)

1. Pyörälä K., Laakso M., Uusitupa M. Diabetes and atherosclerosis: an epidemiological view. Diabetes. Metab. Rev. 3:1987;463-524.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
3. Rubanyi G.M. The role of endothelium in cardiovascular homeostasis and diseases. J. Cardiovasc. Pharmacol. 22(Suppl 4):1993;S1-S14.
4. Flavahan N.A. Atherosclerosis or lipoprotein-induced endothelial dysfunction. Circulation. 85:1992;1927-1938.
5. Celermajer D.S. Endothelial dysfunction - does it matter? Is it reversible? J. Am. Coll. Cardiol. 30:1997;325-333.
6. Cohen R.A. Dysfunction of vascular endothelium in diabetes mellitus. Circulation. 87(Suppl V):1993;V67-V76.
7. Semenkovich C.F., Heinecke J.W. The mystery of diabetes and atherosclerosis. Time for a new plot. Diabetes. 46:1997;327-334.
8. Chowienczyk P.J., Watts G.F. Endothelial dysfunction, insulin resistance and non-insulin-dependent diabetes. Endocrinol. Metab. 4:1997;221-223.
9. Jaap A.J., Tooke J.E. Pathophysiology of microvascular disease in non-insulin-dependent diabetes. Clin. Sci. 89:1995;3-12.
10. Pinkey J.H., Stehouwer C.D.A., Coppack S.W., Yudkin J.S. Endothelial dysfunction-cause of the insulin resistance syndrome. Diabetes. 46(Suppl 2):1997;S9-S13.
11. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43:1991;109-142.
12. Cooke J.P., Tsao P.S. Is NO and endogenous antiatherogenic molecule? Arterioscler. Thromb. 14:1994;653-655.
13. Creager M.A., Cooke J.P., Mendelsohn M.E., Golagler S.J., Coleman S.M., Loscalzo J. et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolaemic humans. J. Clin. Invest. 86:1990;228-234.
14. Chowienczyk P.J., Watts G.F., Cockcroft R.J., Ritter J.M. Impaired endothelium-dependent vasodilatation of forearm resistance vessels in hypercholesterolaemia. Lancet. 340:1992;1430-1432.
15. Celermajer D.S., Sorensen K.E., Georgakopoulos D., Bull C., Thomas O., Robinson J. et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilatation in healthy young adults. Circulation. 88:1993;2149-2155.
16. Panza J.A., Quyyumi A.A., Brush J.E., Epstein S.E. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Eng. J. Med. 323:1990;27-36.
17. Johnstone M.T., Creager S.J., Seales K.M., Cusco J.A., Lee B.K., Creager M.A. Impaired endothelium-dependent vasodilatation in patients with insulin-dependent diabetes mellitus. Circulation. 88:1993;2510-2516.
18. Williams S.B., Cuseo J.A., Roddy M.-A., Johnstone M.T., Creager M.A. Impaired nitric-oxide mediated vasodilatation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 27:1996;567-574.
19. Celermajer D.S., Sorensen K.E., Bull C., Robinson J., Deanfield S.E. Endothelium-dependent dilatation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J. Am. Coll. Cardiol. 24:1994;1465-1474.
20. Lieberman E.H., Gerhard M.D., Uehata A., Walsh B.W., Selwyn A.P., Ganz P. et al. Estrogen improves endothelium-dependent flow-mediated vasodilation in postmenopausal women. Ann. Intern. Med. 121:1994;936-941.
21. Celermajer D.S., Sorensen K.E., Spiegelhalter D.J., Georgakopoulos D., Robinson J., Deanfield J.E. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J. Am. Coll. Cardiol. 24:1994;471-476.
22. Clarkson P., Celermajer D.S., Powe A.J., Donald A.E., Henry R.M.A., Deanfield J.E. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation. 96:1997;3378-3383.
23. Kari J.A., Donald A.E., Vallance D.T., Bruckdorfer K.R., Leone A., Mullen M.J. et al. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kid. Int. 52:1997;468-472.
24. Woo K.S., Chook P., Lolin Y.I., Cheung A.S.P., Chan L.T., Sun Y.Y. et al. Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 96:1997;2542-2544.
25. Poston L., Taylor P.D. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin. Sci. 88:1995;245-255.
26. McNally P.C., Watt P.A.C., Rimmer T., Burden A.C., Hearnshaw J.R., Thurston H. Impaired contraction and endothelium-dependent relaxation in isolated resistance vessels from patients with insulin-dependent diabetes. Clin. Sci. 87:1994;31-36.
27. Sorensen K.E., Celermajer D.S., Spiegelhalter D.J., Georgakopoulos D., Robinson T., Thomas O. et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br. Heart. J. 74:1995;247-253.
28. Benjamin N., Calver A., Collier J., Robinson B., Vallance P., Webb D. Measuring forearm blood flow and interpreting the response to drugs and mediators. Hypertension. 25:1995;918-923.
29. Anderson T.J., Uehata A., Gerhard M.D., Meredith I.T., Knab S., Delagrange E.D. et al. Close relation of endothelial function in the human coronary and peripheral circulation. J. Am. Coll. Cardiol. 26:1995;1235-1241.
30. Sax F.L., Cannon R.D., Hanson C., Epstein S.E. Impaired forearm vasodilator reserve in patients with microvascular angina. Evidence of a generalized disorder of vascular function? N. Eng. J. Med. 317:1987;1366-1370.
31. Zeiher A.M., Drexler H., Bernward S., Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolaemia, and hypertension. J. Clin. Invest. 92:1993;652-662.
32. Egashira K., Inou T., Hirooka Y., Yamada A., Maruoka Y., Kai H. et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J. Clin. Invest. 91:1993;29-37.
33. Nitenberg A., Valensi P., Sacks R., Dali M., Aptecar E., Attali J.R. Impairment of coronary vascular reserve and ACh-induced coronary vasodilatation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes. 42:1993;1017-1025.
34. Morris S.J., Shore A.C., Tooke J.E. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia. 38:1995;1337-1344.
35. Stehouwer C.D.S., Stroes E.S.G., Hacking W.H.L., Mulder P.G.M., Den Ottolander G.J.M. Von Willebrand factor and development of diabetic nephropathy in IDDM. Diabetes. 40:1991;971-976.
36. Jensen T., Feldt-Rasmussen B., Bjerre-Knudsen J., Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet. i:1989;461-463.
37. Taskinen M.-R. Dyslipidaemia in non-insulin-dependent diabetes. Cardiovasc. Risk. Factors. 5:1995;22-29.
38. Syvänne M., Taskinen M.-R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet. 350(Suppl 1):1997;20-23.
39. Assmann G., Shulte H. Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Munster Study. Am. J. Cardiol. 70:1992;104-137.
40. Lehto S., Rönneman T., Haffner S.M., Pyörälä K., Kallio V., Laakso M. Dyslipidaemia and hyperglycaemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 46:1997;1254-1359.
41. Howard B.V. Lipoprotein metabolism in diabetes mellitus. J. Lipid. Res. 28:1987;613-628.
42. Pfeifer M.A., Brunzell J.D., Best J.D., Judzewitsch R.G., Halter J.B., Porte D. The response of plasma triglyceride, cholesterol, and lipoprotein lipase treatment in non-insulin-dependent diabetic subjects without familial hypertriglyceridaemia. Diabetes. 32:1983;525-531.
43. Cummings M.H., Watts G.F., Umpleby A.M., Hennesy T.R., Kelly J.M., Jackson N.C. et al. Acute hyperinsulinaemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetes. 44:1995;1059-1065.
44. Lewis G.F., Uffelman K.D., Szeto L.W., Steiner G. Effects of acute hyperinsulinaemia on VLDL triglyceride and VLDL apo B production in normal weight and obese individuals. Diabetes. 43:1993;833-842.
45. Malmström R., Packard C.J., Caslake M., Bedford D., Stewart P., Yhei-Jaroinan H. et al. Defective regulation of triglyceride metabolism by insulin in the liver in non-insulin-dependent diabetes mellitus. Diabetologia. 40:1997;454-462.
46. Reaven G.M., Greenfield H.S. Diabetic hypertriglyceridemia. Evidence for three clinical syndromes. Diabetes. 30(Suppl 2):1981;66-75.
47. Taskinen M.R., Beltz W.F., Harper I., Fields R.M., Schonfeld G., Grundy S.M. et al. The effects of non-insulin-dependent diabetes mellitus on VLDL triglyceride and VLDL apo B metabolism: studies before and after sulfonylurea therapy. Diabetes. 35:1986;1268-1277.
48. Lewis G.F., Uffelman K.D., Szeto L.W., Weller B., Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J. Clin. Invest. 95:1995;158-166.
49. Byrne C.D., Brindle N.P.J., Wang T.W.M., Hales C.N. Interaction of non-esterified fatty acid and insulin in control of triacylglycerol secretion by Hep G2 cells. Biochem. J. 280:1991;99-104.
50. Frayn K.N. Insulin resistance and lipid metabolism. Curr. Opin. Lipidol. 4:1993;194-204.
51. Pykalisto O.J., Smith P.H., Brunzell J.D. Determinants of human adipose tissue lipoprotein lipase: effect of diabetes and obesity on basal- and diet-induced activity. J. Clin. Invest. 56:1975;1108-1117.
52. Taskinen M.R. Lipoprotein lipase in diabetes. Diabetes. Metab. Rev. 3:1987;551-570.
53. Ida Chen Y.-D., Reaven G.M. Intestinally-derived lipoproteins: metabolism and clinical significance. Diabetes. Metab. Revs. 7:1991;191-208.
54. Ida Chen Y.-D., Swami S., Skawronski R., Coulston A., Reaven G.M. Differences in postprandial lipemia between patients with normal glucose tolerance and non-insulin dependent diabetes mellitus. J. Endocrinol. Metab. 76:1993;172-177.
55. Howard B.V., Knowler W.C., Vasquez B., Kennedy A.L., Pettit D.J., Bennett P.H. Plasma and lipoprotein cholesterol and triglyceride in the Pima Indian population. Comparison in diabetic and non-diabetics. Arteriosclerosis. 4:1984;461-471.
56. Bagdade J.D., Buchanan W.E., Kuusi T., Taskinen M.-R. Persistent abnormalities in lipoprotein composition in non-insulin-dependent diabetes after intensive insulin therapy. Arteriosclerosis. 10:1990;232-239.
57. Biesbroeck R.C., Albers J.J., Wahl P.W., Weinberg C.R., Bassett M.L., Bierman E.L. Abnormal composition of high density lipoproteins in non-insulin-dependent diabetics. Diabetes. 31:1982;126-131.
58. Elckeby M., Porokhov B., Pulcini T., Berthezene F., Ponsin G. Alterations in composition and concentration of lipoproteins and elevated cholesteryl ester transfer in non-insulin-dependent diabetes mellitus (NIDDM). Atherosclerosis. 123:1996;93-101.
59. Kahri J., Syvanne M., Taskinen M.-R. Plasma cholesteryl ester transfer protein activity in non-insulin-dependent diabetic patients with and without coronary artery disease. Metabolism. 43:1994;1498-1502.
60. Harno K., Nikkilä E.A., Kuusi T. Plasma HDL-cholesterol and postheparin plasma hepatic endothelial lipase (HL) activity: relationship to obesity and non-insulin dependent diabetes (NIDDM). Diabetologia. 19:1980;281.
61. Zambon A., Austin M.A., Brown B.G., Hokanson J.E., Brunzell J.D. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler. Thromb. 13:1993;147-153.
62. Feingold K.R., Grunfeld C., Pang M., Doerrler W., Krauss R.M. LDL subclass phenotype and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler. Thromb. 12:1992;1496-1502.
63. Singh A., Rainwater D.L., Haffner S.M., VandeBerg J.L.W.R., Moore P.H., Dyer T.D. Effect of diabetes on lipoprotein size. Arterioscler. Thromb. Vasc. Biol. 15:1995;1805-1811.
64. Brinton E.A., Eisenberg S., Breslow J.L. Human HDL cholesterol levels are determined by apo A-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size: effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler. Thromb. 14:1994;707-720.
65. Tan K.C., Cooper M.B., King K.L., Griffin B.A., Freeman D.J., Packard C.J. et al. Fasting and post-prandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvements of insulin, insulin precursor species and insulin resistance. Atherosclerosis. 113L:1995;273-287.
66. Watts G.F., Mandalia S., Brunt J.N.H., Slavin B.M., Coltart D.J., Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St Thomas' Atherosclerosis Regression Study. Metabolism. 42:1993;1461-1467.
67. Tribble D.L., Holl L.G., Wood P.D., Krauss R.M. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis. 93:1992;189-199.
68. de Uraaf J., Hak-Lommers H.L.M., Hectors M.P.C., Demacker P.N.M., Hendriks J.C.M., Stalenhoef A.F.H. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler. Thromb. 11:1991;298-306.
69. Wilson D.E., Hata A., Kwong L.K., Lingam A., Shuhua J., Ridinger D. et al. Mutations in exon 3 of the lipoprotein lipase gene segregating in a family with hypertriglyceridaemia, pancreatitis, and non-insulin-dependent diabetes. J. Clin. Invest. 92:1993;203-211.
70. Laakso M., Kesaniemi A., Kervinen K., Jauhiainen M., Pyörälä K. Relation of coronary heart disease and apolipoprotein phenotype in patients with non-insulin-dependent diabetes. Br. Med. J. 303:1991;1159-1162.
71. Reznik Y., Pousse P., Herron M., Morello R., Mahoudeau J., Drosdowsky M.A. et al. Postprandial lipoprotein metabolism in normotriglyceridaemic non-insulin-dependent diabetic patients: influences of apolipoprotein E polymorphism. Metabolism. 45:1996;63-71.
72. Li W.W., Dammerman M.M., Smith J.D., Metzger S., Breslow J.L., Leff T. Common genetic variation in the promoter of the human apo C-III gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J. Clin. Invest. 96:1995;2601-2605.
73. Ukkola O., Savolainen M.J., Salmela P.I., von Dickhoff K., Kesaniemi Y.A. DNA polymorphisms at the locus for human cholesteryl ester transfer protein (CETP) are associated with macro- and micro-angiography in non-insulin-dependent diabetes mellitus. Clin. Genetics. 46:1994;217-227.
74. Wolff S.P. Diabetes mellitus and free radicals Free radicals transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br. Med. J. 49:1993;642-652.
75. Giugliano D., Ceriello A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes. Care. 19:1996;257-267.
76. Hunt J.V., Dean R.T., Wolff S.D. Hydroxyl radical production and antioxidative glycosylation: glucose autoxidation in the experimental glycation model of diabetes mellitus and ageing. Biochem. J. 256:1988;205-212.
77. Vlassara H. Recent progress on the biology and clinical significance of advanced glycosylation end products. J. Lab. Clin. Med. 124:1994;19-30.
78. Lee T.S., Saltsman K.A., Ohashi H., King G.L. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanisms in the development of diabetic vascular complications. Proc. Natl. Acad. Sci. USA. 86:1989;5141-5145.
79. Feener E.P., King G.L. Vascular dysfunction in diabetes mellitus. Lancet. 350(Suppl 1):1997;9-13.
80. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA. 87:1990;1620-1624.
81. Hawthorne G.C., Bartlett K., Hetherington C.S., Alberti K.G.M.M. The effect of high glucose on polyol pathway activity and myo-inositol metabolism in cultured human endothelial cells. Diabetologia. 32:1989;163-166.
82. Harlan J.M., Levine J.D., Callahan K.S., Schwartz B.R., Harber L.A. Glutathione redox cycle protects cultured endothelial cells against lysis by extracellulary generated hydrogen peroxide. J. Clin. Invest. 73:1984;706-713.
83. Wohaieb S.A., Godin D.V. Alterations in the free radical tissue-defense mechanisms in streptozotocin-induced diabetes in rat. Diabetes. 36:1987;1014-1018.
84. Nourooz-Zadeh J., Tajaddini-Sarmadi J., McCarthy S., Betteridge D.J., Wolff S.P. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes. 44:1995;1054-1058.
85. Nourooz-Zadeh J., Rahimi A., Tajaddini-Sarmadi J., Tritschler H., Rosen P., Halliwell B. et al. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia. 40:1997;647-653.
86. Griffin M.E., McInerney D., Fraser A., Johnson A.H., Collins P.B., Owens G.H. Autoantibodies to oxidized low density lipoprotein: the relationship to low density lipoprotein fatty acid composition in diabetes. Diabet. Med. 14:1997;741-747.
87. Gopaul N.K., Änggård E.E., Mallet A.I., Betteridge D.J., Wolff S.P., Nourooz-Zadeh J. Plasma 8-epi-PGF2α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS. Lett. 368:1995;225-229.
88. Barrett-Connor E. Does hyperglycaemia really cause coronary heart disease? Diabetes. Care. 20:1997;1620-1623.
89. Griendling K.K., Alexander R.W. Oxidative stress and cardiovascular disease. Circulation. 96:1997;3264-3265.
90. McVeigh G.E., Brennan G.M., Johnston G.D., McDermott B.J., McGrath L.T., Henry W.R. et al. Impaired endothelium-dependent and independent vasodilatation in patients with Type 2 (non-insulin dependent) diabetes mellitus. Diabetologia. 35:1992;771-776.
91. Goodfellow J., Ramsey M.W., Luddington L.A., Jones C.J.H., Coates P.A., Dunstan F. et al. Endothelium and inelastic arteries: an early marker of vascular dysfunction in non-insulin-dependent diabetes. Br. Med. J. 312:1996;744-745.
92. Steinberg H.O., Chaker H., Leaming R., Johnson A., Brechtel G., Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 97:1996;2601-2610.
93. Stehouwer C.D.S., Nauta J.J.P., Zeldenrust G.C., Hacking W.H.L., Donker A.J.M., Den Ottolander G.J.M. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 340:1992;319-323.
94. De Tejada S., Goldstein I., Azadzoi K., Krane R.J., Cohen R.A. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N. Eng. J. Med. 320:1989;1025-1030.
95. Sorensen K.E., Kristensen I.B., Celermajer D.S. Atherosclerosis in the human brachial artery. J. Am. Coll. Cardiol. 29:1997;318-322.
96. Keaney J.F., Schwaery G.T., Xu A., Nicolosi R.J., Loscalzo J., Foxall T.L. et al. 17β-estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolaemic swine. Circulation. 89:1994;2251-2254.
97. Edwards G., Weston A.H. Potassium channel openers and vascular smooth muscle relaxation. Pharmacol. Ther. 48:1990;237-258.
98. Sundaresan P., Lykos D., Daker A., Morris R., Diamond T., Howes L.G. Acute effects of oral glibenclamide on blood pressure and forearm vascular resistance in diabetics. Clin. Exp. Pharmacol. Phys. 24:1997;333-335.
99. Scherrer U., Randin D., Vollenweider L., Nicol P. Nitric oxide release accounts for insulin's vascular effects in humans. J. Clin. Invest. 94:1994;2511-2515.
100. Laakso M., Edelman S.V., Brechtel G., Baron A.D. Decreased effects of insulin to stimulate skeletal muscle blood flow in obese man: a novel mechanism for insulin resistance. J. Clin. Invest. 85:1990;1844-1853.
101. Petrie J.R., Ueda S., Webb D.J., Elliot H.L., Connell J.M.C. Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation. 110:1996;736-738.
102. Utriainen T., Makimattila S., Virkamaki A., Bergholm R., Yki-Jarvinen H. Dissociation between insulin sensitivity of glucose uptake and endothelial function in normal subjects. Diabetologia. 39:1996;1477-1482.
103. Watts G.F., O'Brien S.F., Silvester W., Millar J.A. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin. Sci. 91:1996;567-573.
104. O'Brien S.F., Watts G.F., Playford D.A., Burke V., O'Neal D.N., Best J.D. Low-density lipoprotein size, high-density lipoprotein concentration, and endothelial dysfunction in non-insulin-dependent diabetes. Diabetic. med. 14:1997;974-978.
105. Navab M., Berliner J.S., Watson A.D., Hama S.Y., Territo M.C.V., Lusis A.J. et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol. 16:1996;831-842.
106. Jessup W. Oxidized lipoproteins and nitric oxide. Curr. Op. Lipidol. 7:1996;274-280.
107. Barter P.J., Rye K.-A. High density lipoproteins and coronary heart disease. Atherosclerosis. 121:1996;1-12.
108. Banka C.L. High density lipoprotein and lipoprotein oxidation. Curr. Opin. Lipidol. 7:1996;139-142.
109. Kawamura M., Heinecke J.W., Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J. Clin. Invest. 94:1994;771-778.
110. Bowie A., Owens D., Collins P., Johnson A., Tomkin G.H. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patients? Atherosclerosis. 102:1993;63-67.
111. Lopes-Virella M.F., Virella G. Modified lipoproteins, cytokines and macrovascular disease in non-insulin-dependent diabetes mellitus. Ann. of. Medicine. 28:1996;347-354.
112. Jacobs M., Plane F., Bruckdorfer K.R. Native and oxidised low density lipoproteins have different inhibitory effects on endothelium-derived relaxing factor in the rabbit aorta. Br. J. Pharmacol. 100:1990;21-26.
113. Liao J.K., Shin W.S., Lee W.Y., Clark S.L. Oxidized low density lipoprotein decreases the expression of endothelial nitric oxide synthase. J. Biol. Chem. 270:1995;319-324.
114. Ohara Y., Sayegh H.S., Yamin J.J., Harrison D.G. Regulation of endothelial constitutive nitric oxide synthase by protein kinase C. Hypertens. 25:1995;415-420.
115. 1 proteins by low density lipoproteins attenuates bradykinin stimulated release of endothelial derived nitric oxide. J. Biol. Chem. 269:1994;12987-12992.
116. 12 subunit expression by oxidised low-density lipoprotein. J. Clin. Invest. 95:1995;1457-1463.
117. Ju H., Zou R., Venema V.J., Venema R.C. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J. Biol. Chem. 272:1997;18522-18525.
118. Garcia-Cardena G., Martasek P., Masters B.S., Skidd P.M., Couet J., Li S. et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the NOS caveolin binding domain in vivo. J. Biol. Chem. 272:1997;25437-25440.
119. Michel J.B., Feron O., Sase K., Prabhakar P., Michel T. Caveolin versus calmodulin. Counterbalancing allosteric modulations of endothelial nitric oxide synthase. J. Biol. chem. 272:1997;25907-25912.
120. Wever R.M.F., Lüscher T.F., Cosentino F., Rabelink T.J. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation. 97:1998;108-112.
121. Bist A., Fielding P.E., Fielding C.J. Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response of low density lipoprotein free cholesterol. Proc. Natl. Acad. Sci. 94:1997;10693-10698.
122. Boulanger C.M., Tanner F.C., Bea M.L., Hahn A.W., Werner A., Luscher T.F. Oxidised low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ. Res. 70:1992;1191-1197.
123. Pritchard K.A., Groszek L., Smalley D.H., Sessa W.C., Wu M., Villalon P. et al. Native low density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ. Res. 77:1995;510-518.
124. Bode-Boger S.M., Boger R.H., Kienke S., Junker W., Brohoh J.C. Elevated L-arginine dimethyl-arginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolaemic rabbits. Biochem. Biophys. Res. Commum. 219:1996;598-603.
125. Takahara N., Kashiwagi A., Nishio Y., Harada N., Kojima H., Maegawa H. et al. Oxidized lipoproteins found in patients with NIDDM stimulates radical-induced monocyte chemoattractant protein-1 mRNA expression in cultured human endothelial cells. Diabetologia. 40:1997;662-670.
126. Anderson T.J., Meredith I.T., Yeung A.C., Charbonneau F., Selwyn A.P., Ganz P. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation. 93:1996;1647-1650.
127. Raitakari O.T., Pitkänen O.P., Lehtimäki T., Lahdenperä S., Iida H., Ylä-Herttuala S. et al. In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. J. Am. Coll. Cardiol. 30:1997;97-102.
128. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P. The effect of cholesterol lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Eng. J. Med. 322:1995;488-493.
129. Parthasarathy S., Barnett J., Fong L.G. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim. Biophys. Acta. 1044:1990;275-283.
130. Mackness M.I., Abbott C.A., Arrol S., Durrington P.N. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem. J. 294:1993;829-835.
131. Klimov A.N., Gurevich V.S., Nikoforava A.A., Shatilina L.V., Kuzmin A.A., Plavinsky S.L. et al. Antioxidative activity of high density lipoproteins in vivo. Atherosclerosis. 100:1993;13-18.
132. Van Lenten B.J., Hama S.Y., De Beer F.C., Stafforini D.M., McIntyre T.M., Prescott S.M. et al. Antinflammatory HDL becomes proinflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96:1995;2758-2767.
133. Mackness M.I., Durrington P.N. High density lipoprotein, its enzymes and their potential to influence lipid peroxidation. Atherosclerosis. 115:1995;243-253.
134. Mackness M.I., Durrington P.N. Paraoxonase: another factor in NIDDM cardiovascular disease. Lancet. 346:1995;856.
135. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship with serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15:1995;1812-1818.
136. Odawara M., Tachi Y., Yamashita K. Paraoxonase polymorphism (gln 192-Arg) is associated with coronary heart disease in Japanese non-insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:1997;2257-2260.
137. Fleisher L.N., Tall A.R., Witte L.D., Muller R.W., Cannon P.J. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J. Biol. Chem. 257(12):1982;6653-6655.
138. Galle J., Ochslen M., Schillmeyer P., Warner C. Oxidised lipoproteins inhibit endothelium-dependent vasodilation. Effects of pressure and high-density-lipoproteins. Hypertens. 23:1994;556-564.
139. Zeiher A.M., Schachinger V., Hohnloser S.M., Saurbier B., Just M. Coronary atherosclerosis wall thickening and vascular reactivity in humans. Elevated high density lipoproteins ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation. 89:1994;2525-2532.
140. Maier J.A.M., Barenghi L., Pagani F., Bradomante S., Comi P., Rognotti G. The protective role of high-density lipoprotein on oxidized-low-density-lipoprotein induced U937/endothelial cell interactions. Eur. J. Biochem. 221:1994;35-41.
141. Chowienczyk P.J., Watts G.F., Wierzbicki A.S., Cockcroft J.R., Brett S.E., Ritter J.M. Preserved endothelial function in patients with severe hypertriglyceridaemia and low functional lipoprotein lipase activity. J. Am. Coll. Cardiol. 29:1997;964-968.
142. Chin J.H., Azhar S., Hoffman B.B. Inactivation of endothelial derived relaxing factor by oxidised lipoproteins. J. Clin. Invest. 89:1992;10-18.
143. Christison J., Karjalainen A., Brauman J., Bygrave F., Stocker R. Rapid reduction and removal of HDL- but not LDL- associated cholesteryl ester hydroperoxides by rat liver perfused in situ. Biochemi. J. 314:1996;739-742.
144. Francis G.A., Oram J.F., Heinecke J.W., Bierman E.L. Oxidative tyrosylation of HDL enhances the depletion of cellular cholesteryl esters by a mechanism independent of passive sterol desorption. Biochemistry. 35:1996;15188-15197.
145. Doi H., Kugiyama K., Ohta Y., Matsumura T., Sugiyama S., Nakano T. et al. Remnants of chylomicron and VLDL impair endothelium-dependent vasorelaxation. Circulation. 92(Suppl 1):1995;39.
146. Vogel R.A., Corretti M.C., Plotnick F.D. Effect of a single high-fat meal on endothelial function in healthy subjects. Am. J. Cardiol. 79:1997;350-354.
147. Lundman P., Eriksson M., Schenck-Gustafsson K., Karpe F., Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation. 96:1997;3266-3268.
148. Clarkson P., Celermajer D.S., Donald A.E., Sampson M., Sorensen K.E., Adams M. et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. 28:1996;573-579.
149. Giugliano D., Paolisso G., Coppola L. Hyperglycaemia and endothelial dysfunction in human diabetes: does oxidative stress play a role? Nutr. Metab. Cardiovasc. Dis. 7:1997;100-104.
150. Tribe R.M., Poston L. Oxidative stress and lipids in diabetes: a role in endothelium vasodilator dysfunction? Vasc. Med. 1:1996;195-206.
151. Tesfamarian B., Cohen R.A. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am. J. Physiol. 263:1992;H321-H326.
152. Angulo J., Sanchez-Ferrer C.F., Peiro C., Marin J., Rodriguez-Manas L. Impairment of endothelium dependent relaxation by increasing percentages of glycosylated hemoglobin. Hypertens. 28:1996;583-592.
153. Ting H.H., Timini F.K., Boles K.S., Creager S.J., Ganz P., Creager M.A. Vitamin C improves endothelium-dependent vasodilatation in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 97:1996;22-28.
154. Regnström J., Ström K., Moldeus P., Nilsson J. Analysis of lipoprotein diene formation in human serum exposed to copper. Free. Rad. Res. Comms. 19:1993;267-278.
155. Tesfamarian B., Brown M.L., Deykin D., Cohen R.A. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J. Clin. Invest. 85:1990;929-932.
156. Wautier J.L., Wautier M.P., Schmidt A.M., Anderson G.M., Hori G., Zoukourian C. et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc. Natl. Acad. Sci. USA. 91:1994;7742-7746.
157. Bucala R., Makita Z., Koschinsky T., Cerami A., Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc. Natl. Acad. Sci. USA. 90:1993;6434-6438.
158. Bucala R., Tracey K.J., Cerami A. Advanced glycosylation end products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest. 87:1991;432-438.
159. Bucala R., Makita A., Vega G., Grundy S., Koschinsky T., Cerami A. et al. Modification of low density lipoprotein contributes to the dyslipidaemia of diabetes and renal insufficiency. Proc. Natl. Acad. Sci. USA. 91:1994;9441-9445.
160. Jandeleit K., Rumble J., Jackson B., Cooper M.E. Mesenteric vascular angiotensin-converting enzyme is increased in experimental diabetes mellitus. Clin. Exp. Pharmacol. Physiol. 19:1992;343-347.
161. Griendling K., Ollerenshaw J.D., Minieri C., Alexander R.W. Angiotensin II stimulates NADH and NADPH activity in cultured vascular smooth muscle cells. Circ. Res. 74:1994;1141-1148.
162. Chowienczyk P.J., Barnes D.J., Brett S.E., Cockcroft J.R., Viberti G.C., Ritter J.M. Correction of impaired NO mediated vasodilation by L-arginine in non-insulin-dependent diabetes. Endothelium. 3:1995;595.
163. Reaven G. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes. 37:1988;1545-1607.
164. Ferrannini E., Haffner S.M., Mitchell B.D., Stern M.P. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 34:1991;416-422.
165. Popper K. The Logic of Scientific Discovery (Logik der Forschung, 1935). 1959;Hutchinson, London.
166. Cockcroft J.R., Chowienczyk P.J., Benjamin N., Ritter J.H. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N. Eng. J. Med. 330:1994;1036-1040.
167. Umans J.G. Less nitric oxide, more pressure, or the converse? Lancet. 349:1997;816-817.
168. Plotnick G.D., Corretti M.C., Vogel R.A. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single light-fat meal. J. Am. Med. Assoc. 278:1997;1682-1686.
169. American Diabetes Association Consensus Statement. Detection and management of lipid disorders in diabetes. Diabetes Care 1996;19(Suppl 1):S96-S102.
170. Best J.D., Jerums G., Newnham H.H., O'Brien R.C. Diabetic dyslipidaemia. Australian Diabetes Society position statement. Med. J. Aus. 162:1995;91-93.
171. Koskinen P., Mänttäri H., Manninen V., Huttunen J.K., Heinonen O.P., Frick M.H. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes. Care. 15:1992;820-825.
172. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica J, Warnold JMO, Wun C-C, Davis BR, Braunwald E, for the CARE Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996;335:1001-1004.
173. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, The Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997;20:614-620.
174. Pyörälä K., Steiner G. Will correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes? Need for trial evidence. Ann. Med. 28:1996;357-362.
175. Treasure C.B., Klein J.L., Weintraub W.S., Talley D.J., Stillabower M.E., Kosinski A.S. et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Eng. J. Med. 332:1995;481-487.
176. Seiler C., Suter T.M., Hess O.M. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J. Am. Coll. Cardiol. 26:1995;1615-1622.
177. Stroes E.S., Koomans H.A., de Bruin J.W., Rebelink T.J. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid lowering medication. Lancet. 346:1995;457-471.
178. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
179. Vogel R.A., Corretti M.C., Plotnick G.D. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am. J. Cardiol. 77:1996;37-40.
180. Jaap A.J., Pym C.A., Seamark C., Shore A.C., Took J.E. Microvascular function in type 2 (non-insulin-dependent) diabetes: improved vasodilatation after one year of good glycaemic control. Diabet. Med. 12:1995;1086-1091.
181. Marfella R., Acampora R., Verrazzo G., Ziccardi P., DeRosa N., Giunta R. et al. Metformin improves hemodynamic and rheological responses to l-arginine in NIDDM patients. Diabetes. Care. 19:1996;934-939.
182. Kingwell B.A., Sherrard B., Jennings G.L., Dart A.M. Four weeks of cycle training increases basal production of nitric oxide from the forearm. Am. J. Physiol. 272:1997;H1070-H1077.
183. McVeigh G.E., Brennan G.M., Johnston G.D., McDermott B.J., McGrath L.T. et al. Dietary fish oil augments with nitric oxide production or release in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 36:1993;33-38.
184. Clarkson P., Adams M.R., Powe A., Donald A., McCredie R., Robinson J. et al. Oral L-arginine improves endothelium-dependent dilatation in hypercholesterolaemic young adults. J. Clin. Invest. 1994-1997:1989;1006.
185. Stroes E., Kastelain J., Cosentino F., Erlekus W., Wever R., Koomans H. et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolaemia. J. Clin. Invest. 99:1997;41-46.
186. Rajagopalan S., Harrison D.G. Reversing endothelial dysfunction with ACE inhibitors. A new TREND? Circulation. 94:1996;240-243.
187. O'Driscoll G., Green D., Rankin J., Stanton K., Taylor R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J. Clin. Invest. 100:1997;678-684.
188. Ritter J.M., Cockcroft J.R. Angiotensin II-receptor (ATI) blockade in the human forearm. Blood. Pressure. 2:1996;67-70.
189. Nolan J.J., Ludvick B., Beerdsen P., Joyce M., Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Eng. J. Med. 331:1994;1188-1193.
190. Noguchi N., Sakai H., Kato Y., Tsuchiya J., Yamamoto Y., Niki E. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis. 123:1996;227-234.
191. Levine G.N., Keaney J.F., Vita J.A. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N. Eng. J. Med. 332:1995;512-521.
192. Hasdai D., Gibbons R.J., Holmes D.R., Higano S.T., Lerman A. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation. 96:1997;3390-3395.
193. Elliott T.G., Cockcroft J.R., Groop P.H., Viberti G.C., Ritter J.M. Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin. Sci. 85:1993;687-693.
194. Smits P., Kapma J., Jacobs M., Lutterman J., Thien T. Endothelium-dependent vascular relaxation in patients with type 1 diabetes. Diabetes. 42:1993;148-153.
195. Lambert J., Aarsen M., Donker A.J.M., Stehouwer C.D.A. Endothelium-dependent and -independent vasodilatation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 16:1996;705-711.
196. Tooke J.E. Microvascular function in human diabetes. A physiological perspective. Diabetes. 44:1995;721-726.
197. Haffner S.M., Mykkänen L.P., Stern M.P., Paidi M., Howard B.V. Greater effect of diabetes on LDL size in women that in men. Diabetes. Care. 17:1994;1164-1171.
198. Hennekens C.H., Gaziano J.M., Monson S.E., Buring J.E. Antioxidant vitamin-cardiovascular disease hypothesis is still promising, but still unproven: the need for randomized trials. Am. J. Clin. Nutr. 62:1995;1377S-1380.
199. The Diabetes Control and Complications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993;329:977-986.
200. Hardie K.L., Kinlay S., Hardy D.B., Wlodarczyk J., Silberberg J.C., Fletcher P.J. Reproducibility of brachial ultrasonography and flow-mediated dilatation (FMD) for assessing endothelial function. Aus. NZ. J. Med. 27:1997;649-652.
201. Playford DA, Watts GF. Non-invasive measurement of endothelial function. Clin Exp Physiol Pharmacol 1998 (in press).